bioAffinity Technologies Expands Access to Lung Cancer Test

bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.

bioAffinity Technologies, Inc. has announced the inclusion of its noninvasive lung cancer detection test, CyPath® Lung, on the U.S. Federal Supply Schedule, granting easy access to VHA and Military Health System facilities. This significant move will cater to the high demand for early cancer detection among veterans, who are at an increased risk of lung cancer due to various factors such as age and environmental exposures. The test, which boasts high accuracy and has the potential to save millions in healthcare costs, represents a major advancement in the quest for better cancer treatment and patient survival outcomes.

See more insights into BIAF stock on TipRanks’ Stock Analysis page.